A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605

Older acute myeloid leukemia (AML) patients with a chromosome 5q deletion have poor outcomes with conventional chemotherapy. This phase 2 study explored the safety and efficacy of single-agent lenalidomide in previously untreated older AML patients with del(5q) who declined standard chemotherapy. Pa...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Sekeres, Mikkael A., Gundacker, Holly, Lancet, Jeffrey, Advani, Anjali, Petersdorf, Stephen, Liesveld, Jane, Mulford, Deborah, Norwood, Tom, Willman, Cheryl L., Appelbaum, Frederick R., List, Alan F.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Hematology 2011
נושאים:
Clinical Trials and Observations
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3142897/
https://ncbi.nlm.nih.gov/pubmed/21551228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-02-337303
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים